Insulet outlines 21%–23% Omnipod revenue growth for 2026 with operating margin expansion, driven by global adoption and product innovation

Q4 2025 Management View Ashley McEvoy, CEO, reported "we closed 2025 with another strong quarter, recording our 10th consecutive year of 20% or greater constant currency revenue growth," citing ...
Seeking Alpha

Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above

OAKVILLE, ON, April 7, 2025 /CNW/ - Insulet Corporation (PODD), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Omnipod 5 is now ...
Nasdaq

Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...